Serum Galectin-3 in Women With Gestational Hypertension and Preeclampsia and Its Association With Preterm Birth

Dolina Gencheva; Fedya Nikolov; Ekaterina Uchikova; Rosen Mihaylov; Blagovesta Pencheva; Gita  Yamakova-Vladova

doi:10.18502/acta.v59i9.7554

Dolina Gencheva First Department of Internal Diseases, Section of Cardiology, Medical University - Plovdiv, Plovdiv, Bulgaria
Fedya Nikolov First Department of Internal Diseases, Section of Cardiology, Medical University - Plovdiv, Plovdiv, Bulgaria
Ekaterina Uchikova Department of Obstetrics and Gynaecology, Medical University - Plovdiv, Plovdiv, Bulgaria
Rosen Mihaylov Independent Medical Diagnostic Laboratory “RAMUS”, Sofia, Bulgaria
Blagovesta Pencheva Independent Medical Diagnostic Laboratory “RAMUS”, Sofia, Bulgaria
Gita Yamakova-Vladova Department of Obstetrics and Gynaecology, Medical University - Plovdiv, Plovdiv, Bulgaria

DOI: https://doi.org/10.18502/acta.v59i9.7554

Keywords: Preeclampsia; Gestational hypertension; Cardiovascular disease; Pregnancy; Galectin-3

Abstract

Hypertensive disorders of pregnancy are one of the leading causes of fetal and maternal mortality worldwide. Aside from the immediate risk they pose for the pregnant woman, there is significant evidence that women after such a pregnancy have a long-term risk for the development of cardiovascular diseases. On the other hand, Galectin-3 is a biomarker that has proven its role in cardiac remodeling, fibrosis, and heart failure. To determine the levels of Galectin-3 in women with gestational hypertension, preeclampsia, and in healthy pregnant women and test for association with premature birth. A prospective single-center clinical, epidemiological study was performed, and data were analyzed for 123 pregnant women-36 with gestational hypertension, 37 with preeclampsia, and 50 controls. ELISA method was used to determine the serum levels of Galectin-3. Mean Galectin-3 level was 6,53 ng/ml in the controls, 7.30 ng/ml in the gestational hypertension group, and 7,59 ng/ml in the preeclampsia group. There was a significant difference in the levels between the controls and each of the pathological groups (P<0,05), while the two pathological groups were not statistically different from each other. Additionally, higher Galectin-3 levels were associated with an OR~2.5 for even preterm birth after adjustment for the presence of the two hypertensive disorders of pregnancy. Gestational hypertension and preeclampsia were associated with significantly higher levels of Galectin-3, which could be indicative of cardiovascular dysfunction in those women, and were also related to premature birth.